{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:41:15Z","timestamp":1784097675405,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:00:00Z","timestamp":1590192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s11864-020-00751-x","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T14:02:16Z","timestamp":1590242536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Interventional Liver-Directed Therapy for Neuroendocrine Metastases: Current Status and Future Directions"],"prefix":"10.1007","volume":"21","author":[{"given":"Donna","family":"D\u2019Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jafar","family":"Golzarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamar","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,23]]},"reference":[{"issue":"18","key":"751_CR1","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063\u201372.","journal-title":"J Clin Oncol"},{"issue":"11","key":"751_CR2","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.3390\/jcm8111907","volume":"8","author":"S Dermine","year":"2019","unstructured":"Dermine S, Palmieri L-J, Lavol\u00e9 J, Barr\u00e9 A, Dohan A, Abou Ali E, et al. Non-pharmacological therapeutic options for liver metastases in advanced neuroendocrine tumors. J Clin Med. 2019;8(11):1907.","journal-title":"J Clin Med"},{"issue":"10","key":"751_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol"},{"issue":"8","key":"751_CR4","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1245\/s10434-017-5839-x","volume":"24","author":"M Fairweather","year":"2017","unstructured":"Fairweather M, Swanson R, Wang J, Brais LK, Dutton T, Kulke MH, et al. Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol. 2017;24(8):2319\u201325.","journal-title":"Ann Surg Oncol"},{"key":"751_CR5","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3332\/ecancer.2016.662","volume":"10","author":"JM Mota","year":"2016","unstructured":"Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience. 2016;10:662.","journal-title":"Ecancermedicalscience"},{"issue":"3","key":"751_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000461583","volume":"105","author":"G Kaltsas","year":"2017","unstructured":"Kaltsas G, Caplin M, Davies P, Ferone D, Garcia-Carbonero R, Grozinsky-Glasberg S, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology. 2017;105(3):245\u201354.","journal-title":"Neuroendocrinology"},{"key":"751_CR7","unstructured":"Shah H, Benson AB, Lurie RH, Bergsland E, Helen Diller Family U, Berlin JD, et al. National Comprehensive Cancer Network Guidelines Version 1.2019: Neuroendocrine and Adrenal Tumors. 2019. www.nccn.org\/patients."},{"key":"751_CR8","doi-asserted-by":"crossref","unstructured":"Young S, Rivard M, Kimyon R, Sanghvi T. Accuracy of liver ablation zone prediction in a single 2450 MHz 100 watt generator model microwave ablation system: an in human study. Diagn Interv Imaging. 2019.","DOI":"10.1016\/j.diii.2019.10.007"},{"issue":"2","key":"751_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.14218\/JCTH.2017.00059","volume":"6","author":"S Young","year":"2018","unstructured":"Young S, Taylor AJ, Sanghvi T. Post locoregional therapy treatment imaging in hepatocellular carcinoma patients: a literature-based review. J Clin Transl Hepatol. 2018;6(2):189\u201397.","journal-title":"J Clin Transl Hepatol"},{"issue":"4","key":"751_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00261-004-0258-4","volume":"30","author":"A Gillams","year":"2005","unstructured":"Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the middlesex experience. Abdom Imaging. 2005;30(4):435\u201341.","journal-title":"Abdom Imaging"},{"issue":"3","key":"751_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ejrad.2008.08.008","volume":"72","author":"TJ Vogl","year":"2009","unstructured":"Vogl TJ, Naguib NNN, Zangos S, Eichler K, Hedayati A, Nour-Eldin NEA. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol. 2009;72(3):517\u201328.","journal-title":"Eur J Radiol"},{"issue":"1","key":"751_CR12","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","volume":"15","author":"A Frilling","year":"2014","unstructured":"Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8\u201321.","journal-title":"Lancet Oncol"},{"issue":"8","key":"751_CR13","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s00268-002-6663-3","volume":"26","author":"P Hellman","year":"2002","unstructured":"Hellman P, Ladjevardi S, Skogseid B, \u00c5kerstr\u00f6m G, Elvin A. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg. 2002;26(8):1052\u20136.","journal-title":"World J Surg"},{"issue":"1","key":"751_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2214\/ajr.147.1.149","volume":"147","author":"CH Carrasco","year":"1986","unstructured":"Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. Am J Roentgenol. 1986;147(1):149\u201354.","journal-title":"Am J Roentgenol"},{"issue":"4","key":"751_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1245\/ASO.2006.03.071","volume":"13","author":"DA Osborne","year":"2006","unstructured":"Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13(4):572\u201381.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"751_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/107327480601300110","volume":"13","author":"JR Strosberg","year":"2006","unstructured":"Strosberg JR, Choi J, Cantor AB, Kvols LK, Lee H. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006;13(1):72\u20138.","journal-title":"Cancer Control"},{"issue":"11","key":"751_CR17","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s11605-008-0640-6","volume":"12","author":"SC Pitt","year":"2008","unstructured":"Pitt SC, Knuth J, Keily JM, McDermott JC, Weber SM, Chen H, et al. Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg. 2008;12(11):1951\u201360.","journal-title":"J Gastrointest Surg"},{"issue":"4","key":"751_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00270-018-02160-y","volume":"42","author":"R Zener","year":"2019","unstructured":"Zener R, Yoon H, Ziv E, Covey A, Brown KT, Sofocleous CT, et al. Outcomes after transarterial embolization of neuroendocrine tumor liver metastases using spherical particles of different sizes. Cardiovasc Intervent Radiol. 2019;42(4):569\u201376.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"751_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000336941","volume":"96","author":"F Maire","year":"2012","unstructured":"Maire F, Lombard-Bohas C, O\u2019Toole D, Vullierme MP, Rebours V, Couvelard A, et al. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study. Neuroendocrinology. 2012;96(4):294\u2013300.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"751_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00270-016-1478-z","volume":"40","author":"JX Chen","year":"2017","unstructured":"\u2022 Chen JX, Rose S, White SB, El-Haddad G, Fidelman N, Yarmohammadi H, et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc Intervent Radiol. 2017;40(1):69\u201380 Large retrospective study comparing TAE, TACE and TARE for NELM with propensity score analysis.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"751_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12020-013-0130-9","volume":"47","author":"F Fiore","year":"2014","unstructured":"Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014;47(1):177\u201382.","journal-title":"Endocrine"},{"issue":"5","key":"751_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1634\/theoncologist.2011-0372","volume":"17","author":"MA Lewis","year":"2012","unstructured":"Lewis MA, Jaramillo S, Roberts L, Fleming CJ, Rubin J, Grothey A. Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Oncologist. 2012;17(5):725\u201331.","journal-title":"Oncologist"},{"issue":"5","key":"751_CR23","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.2214\/AJR.06.0933","volume":"188","author":"AS Ho","year":"2007","unstructured":"Ho AS, Picus J, Darcy MD, Tan B, Gould JE, Pilgram TK, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. Am J Roentgenol. 2007;188(5):1201\u20137.","journal-title":"Am J Roentgenol"},{"issue":"2","key":"751_CR24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1245\/s10434-016-5591-7","volume":"24","author":"M Dhir","year":"2017","unstructured":"Dhir M, Shrestha R, Steel JL, Marsh JW, Tsung A, Tublin ME, et al. Initial treatment of unresectable neuroendocrine tumor liver metastases with transarterial chemoembolization using streptozotocin: a 20-year experience. Ann Surg Oncol. 2017;24(2):450\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"751_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/sj.bjc.6603526","volume":"96","author":"F Marrache","year":"2007","unstructured":"Marrache F, Vullierme MP, Roy C, El Assoued Y, Couvelard A, O\u2019Toole D, et al. Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer. 2007;96(1):49\u201355.","journal-title":"Br J Cancer"},{"issue":"3","key":"751_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s11605-007-0089-z","volume":"11","author":"M Bloomston","year":"2007","unstructured":"Bloomston M, Al-Saif O, Klemanski D, Pinzone JJ, Martin EW, Palmer B, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg. 2007;11(3):264\u201371.","journal-title":"J Gastrointest Surg"},{"issue":"Suppl 1","key":"751_CR27","doi-asserted-by":"publisher","first-page":"S286","DOI":"10.1007\/s12032-010-9750-6","volume":"28","author":"X Da Dong","year":"2011","unstructured":"Da Dong X, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol. 2011;28(Suppl 1):S286\u201390.","journal-title":"Med Oncol"},{"issue":"7","key":"751_CR28","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jvir.2013.02.030","volume":"24","author":"S Hur","year":"2013","unstructured":"Hur S, Chung JW, Kim HC, Oh DY, Lee SH, Bang YJ, et al. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. J Vasc Interv Radiol. 2013;24(7):947\u201356.","journal-title":"J Vasc Interv Radiol"},{"issue":"12","key":"751_CR29","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1007\/s00330-017-4856-2","volume":"27","author":"D Do Minh","year":"2017","unstructured":"\u2022 Do Minh D, Chapiro J, Gorodetski B, Huang Q, Liu C, Smolka S, et al. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol. 2017;27(12):4995\u20135005 Large retrospective study comparing TACE and TARE for NELM with propensity score analysis.","journal-title":"Eur Radiol"},{"issue":"3","key":"751_CR30","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jvir.2018.12.151","volume":"30","author":"M Soulen","year":"2019","unstructured":"Soulen M, White S, Fidelman N, Garcia-Monaco R, Wileyto E, Avritscher R, et al. Randomized Embolization Trial for NeuroEndocrine Tumors (RETNET): first safety report. J Vasc Interv Radiol. 2019;30(3):S49\u201350.","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"751_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00270-012-0424-y","volume":"36","author":"N Bhagat","year":"2013","unstructured":"Bhagat N, Reyes DK, Lin M, Kamel I, Pawlik TM, Frangakis C, et al. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol. 2013;36(2):449\u201359.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"751_CR32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jhep.2011.09.012","volume":"56","author":"B Guiu","year":"2012","unstructured":"Guiu B, Deschamps F, Aho S, Munck F, Dromain C, Boige V, et al. Liver\/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads. J Hepatol. 2012;56(3):609\u201317.","journal-title":"J Hepatol"},{"issue":"2","key":"751_CR33","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s00270-014-0914-1","volume":"38","author":"J Joskin","year":"2015","unstructured":"Joskin J, de Baere T, Auperin A, Tselikas L, Guiu B, Farouil G, et al. Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor. Cardiovasc Intervent Radiol. 2015;38(2):372\u201380.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"751_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","volume":"31","author":"AS Kennedy","year":"2008","unstructured":"Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y -microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31(3):271\u20139.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"751_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.diii.2018.07.005","volume":"100","author":"S Young","year":"2019","unstructured":"Young S, Taylor A, Golzarian J, Flanagan S, D\u2019Souza D, Sanghvi T. Clinical utility of one month imaging following selective internal radiation therapy. Diagn Interv Imaging. 2019;100(1):39\u201346.","journal-title":"Diagn Interv Imaging"},{"issue":"3","key":"751_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00270-018-2148-0","volume":"42","author":"A Braat","year":"2019","unstructured":"\u2022 Braat A, Kappadath SC, Ahmadzadehfar H, Stothers CL, Frilling A, Deroose CM, et al. Radioembolization with 90Y resin microspheres of neuroendocrine liver metastases: international multicenter study on efficacy and toxicity. Cardiovasc Intervent Radiol. 2019;42(3):413\u201325 Large multicenter retrospective study assessing efficacy and toxicity of radioembolization for NELM.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"751_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejrad.2018.01.012","volume":"100","author":"Z Jia","year":"2018","unstructured":"\u2022 Jia Z, Wang W. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review. Eur J Radiol. 2018;100:23\u20139 Large systematic review study assessing efficacy and toxicity of radioembolization for NELM.","journal-title":"Eur J Radiol"},{"issue":"6","key":"751_CR38","doi-asserted-by":"publisher","first-page":"860","DOI":"10.21037\/jgo.2016.08.04","volume":"7","author":"N Fidelman","year":"2016","unstructured":"Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, et al. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016;7(6):860\u201374.","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"751_CR39","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/SLA.0b013e3181d3d24a","volume":"251","author":"A Saxena","year":"2010","unstructured":"Saxena A, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg. 2010;251(5):910\u20136.","journal-title":"Ann Surg"},{"issue":"6","key":"751_CR40","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jvir.2018.02.002","volume":"29","author":"Y Tomozawa","year":"2018","unstructured":"Tomozawa Y, Jahangiri Y, Pathak P, Kolbeck KJ, Schenning RC, Kaufman JA, et al. Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. J Vasc Interv Radiol. 2018;29(6):858\u201365.","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"751_CR41","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.jvir.2017.05.011","volume":"28","author":"YK Su","year":"2017","unstructured":"\u2022 Su YK, Mackey RV, Riaz A, Gates VL, Benson AB, Miller FH, et al. Long-term hepatotoxicity of yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver. J Vasc Interv Radiol. 2017;28(11):1520\u20136. Retrospective study with long-term follow up (mean 4.1 years) demonstrating long-term hepatotoxicity is common but asymptomatic in most.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"751_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.21037\/jgo.2018.10.05","volume":"10","author":"DA Zuckerman","year":"2019","unstructured":"Zuckerman DA, Kennard RF, Roy A, Parikh PJ, Weiner AA. Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors - a single-institution experience. J Gastrointest Oncol. 2019;10(1):118\u201327.","journal-title":"J Gastrointest Oncol"},{"issue":"12","key":"751_CR43","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.jvir.2019.06.003","volume":"30","author":"BM Currie","year":"2019","unstructured":"Currie BM, Hoteit MA, Ben-Josef E, Nadolski GJ, Soulen MC. Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis. J Vasc Interv Radiol. 2019;30(12):1915\u201323.","journal-title":"J Vasc Interv Radiol"},{"issue":"Suppl 7","key":"751_CR44","doi-asserted-by":"publisher","first-page":"vii72","DOI":"10.1093\/annonc\/mdq290","volume":"21","author":"KE \u00d6berg","year":"2010","unstructured":"\u00d6berg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010;21(Suppl 7):vii72\u201380.","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"751_CR45","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/annonc\/10.suppl_2.S3","volume":"10","author":"K Oberg","year":"1999","unstructured":"Oberg K. Neuroendocrine gastrointestinal tumors-a condensed overview of diagnosis and treatment. Ann Oncol. 1999;10(Suppl 2):S3\u20138.","journal-title":"Ann Oncol"},{"issue":"8","key":"751_CR46","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/MPA.0000000000001115","volume":"47","author":"MC Soulen","year":"2018","unstructured":"Soulen MC, Van Houten D, Teitelbaum UR, Damjanov N, Cengel KA, Metz DC. Safety and feasibility of integrating yttrium-90 radioembolization with capecitabine-temozolomide for grade 2 liver-dominant metastatic neuroendocrine tumors. Pancreas. 2018;47(8):980\u20134.","journal-title":"Pancreas"},{"issue":"9","key":"751_CR47","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/cncr.31192","volume":"124","author":"HS Kim","year":"2018","unstructured":"Kim HS, Shaib WL, Zhang C, Nagaraju GP, Wu C, Alese OB, et al. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. Cancer. 2018;124(9):1992\u20132000.","journal-title":"Cancer"},{"issue":"8","key":"751_CR48","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/cncr.21389","volume":"104","author":"S Gupta","year":"2005","unstructured":"Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104(8):1590\u2013602.","journal-title":"Cancer"},{"issue":"5","key":"751_CR49","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2010-0292","volume":"16","author":"R Whitney","year":"2011","unstructured":"Whitney R, Valek V, Falco Fages J, Garcia A, Narayanan G, Tatum C, et al. Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost. Oncologist. 2011;16(5):594\u2013601.","journal-title":"Oncologist"},{"issue":"2","key":"751_CR50","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/MPA.0000000000000030","volume":"43","author":"ES Engelman","year":"2014","unstructured":"Engelman ES, Leon-Ferre R, Naraev BG, Sharma N, Sun S, O\u2019dorisio TM, et al. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. Pancreas. 2014;43(2):219\u201325.","journal-title":"Pancreas"},{"issue":"1","key":"751_CR51","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s13063-018-2782-5","volume":"19","author":"JX Chen","year":"2018","unstructured":"Chen JX, Wileyto EP, Soulen MC. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials. 2018;19(1):390.","journal-title":"Trials"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00751-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-020-00751-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-00751-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T23:09:57Z","timestamp":1621724997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-020-00751-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,23]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["751"],"URL":"https:\/\/doi.org\/10.1007\/s11864-020-00751-x","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,23]]},"assertion":[{"value":"23 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Donna D\u2019Souza has received compensation from Sirtex and Medtronic for service as a consultant; Jafar Golzarian declares that he has no conflict of interest; Shamar Young has received compensation from Boston Scientific\/BTG\/Galil Medical for service as a consultant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}],"article-number":"52"}}